Search results
Results from the WOW.Com Content Network
They bid the share price up by more than 2% on the day, making it a mirror image of the 2%-plus decline of the S&P 500 index. ... Before you buy stock in Sanofi, consider this:
Get breaking Business News and the latest corporate happenings from AOL. From analysts' forecasts to crude oil updates to everything impacting the stock market, it can all be found here.
No investor can ignore a crushing bottom-line beat and raised profitability guidance.
Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris, France. The corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers ...
Roussel Uclaf S.A. was a French pharmaceutical company and one of several predecessor companies of today's Sanofi. It was the second largest French pharmaceutical company [6] before it was acquired by Hoechst AG of Frankfurt, Germany in 1997, with pharmaceutical operations combined into the Hoechst Marion Roussel (HMR) division in the United States.
Paul Hudson (born 14 October 1967) [2] is a British businessman, and the chief executive (CEO) of Sanofi, the world's fifth largest pharmaceutical company by prescription drug sales. [ 3 ] Early life
The stock of Sanofi SA (NAS:SNY, 30-year Financials) shows every sign of being fairly valued, according to GuruFocus Value calculation.
On Thursday, Sanofi SA (NASDAQ:SNY) reported a second-quarter business operating income of 2.8 billion euros ($3.03 billion), up 3.2% year-over-year and 8.3% in constant currency. The company ...